Autolus TherapeuticsAUTL
Market Cap: $993M
About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Employees: 463
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
75% more call options, than puts
Call options by funds: $121K | Put options by funds: $69K
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
0.67% more ownership
Funds ownership: 66.15% [Q1] → 66.81% (+0.67%) [Q2]
8% less funds holding
Funds holding: 116 [Q1] → 107 (-9) [Q2]
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
45% less capital invested
Capital invested by funds: $1.12B [Q1] → $619M (-$504M) [Q2]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 2 (-3) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for AUTL.